

# TET2 Deficiency Causes Germinal Center Hyperplasia, I and Promotes B-cell Lymphomagenesis

Cancer Discovery

8, 1632-1653

DOI: [10.1158/2159-8290.cd-18-0657](https://doi.org/10.1158/2159-8290.cd-18-0657)

Citation Report

#	ARTICLE	IF	CITATIONS
1	TET2 Deficiency Sets the Stage for B-cell Lymphoma. <i>Cancer Discovery</i> , 2018, 8, 1515-1517.	7.7	4
2	Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis. <i>Cell Reports</i> , 2019, 28, 2480-2490.e4.	2.9	66
3	Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies. <i>Blood</i> , 2019, 134, 1487-1497.	0.6	95
4	<scp>TET</scp> enzymes control antibody production and shape the mutational landscape in germinal centre B cells. <i>FEBS Journal</i> , 2019, 286, 3566-3581.	2.2	37
5	Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. <i>Cancer Discovery</i> , 2019, 9, 872-889.	7.7	36
6	TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair. <i>Frontiers in Oncology</i> , 2019, 9, 210.	1.3	72
7	TET Enzymes and 5hmC in Adaptive and Innate Immune Systems. <i>Frontiers in Immunology</i> , 2019, 10, 210.	2.2	102
8	Molecular pathogenesis of germinal center-derived B cell lymphomas. <i>Immunological Reviews</i> , 2019, 288, 240-261.	2.8	53
9	Germinal center-derived lymphomas: The darkest side of humoral immunity. <i>Immunological Reviews</i> , 2019, 288, 214-239.	2.8	113
10	Values of 5mC, 5hmC, and TET2 for identifying the presence and progression of breast precancerous lesion. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23162.	0.9	8
11	Diminished expression of 5hmC in Reed-Sternberg cells in classical Hodgkin lymphoma is a common epigenetic marker. <i>Leukemia Research</i> , 2020, 96, 106408.	0.4	7
12	Tet2 at the interface between cancer and immunity. <i>Communications Biology</i> , 2020, 3, 667.	2.0	50
13	Harnessing lymphoma epigenetics to improve therapies. <i>Blood</i> , 2020, 136, 2386-2391.	0.6	5
14	Ascorbic Acid Promotes Plasma Cell Differentiation through Enhancing TET2/3-Mediated DNA Demethylation. <i>Cell Reports</i> , 2020, 33, 108452.	2.9	23
15	Harnessing lymphoma epigenetics to improve therapies (article not eligible for CME credit). <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 95-100.	0.9	6
16	Genetic and epigenetic determinants of diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 123.	2.8	47
17	Epigenetics of the antibody and autoantibody response. <i>Current Opinion in Immunology</i> , 2020, 67, 75-86.	2.4	8
18	Advances in understanding of angioimmunoblastic T-cell lymphoma. <i>Leukemia</i> , 2020, 34, 2592-2606.	3.3	91

#	ARTICLE	IF	CITATIONS
19	Clonal hematopoiesis and non-hematologic disorders. <i>Blood</i> , 2020, 136, 1606-1614.	0.6	71
20	A mosaic analysis system with Cre or Tomato expression in the mouse. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28212-28220.	3.3	3
21	Circles of Life: linking metabolic and epigenetic cycles to immunity. <i>Immunology</i> , 2020, 161, 165-174.	2.0	23
22	DLBCL subclassification: divide and conquer?. <i>Blood</i> , 2020, 135, 1722-1724.	0.6	12
23	The DNA methylation landscape of hematological malignancies: an update. <i>Molecular Oncology</i> , 2020, 14, 1616-1639.	2.1	26
24	Germline TET2 loss of function causes childhood immunodeficiency and lymphoma. <i>Blood</i> , 2020, 136, 1055-1066.	0.6	58
25	TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis. <i>Science Advances</i> , 2020, 6, eaay5872.	4.7	29
26	Advances in targeted therapy for malignant lymphoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 15.	7.1	66
27	Hypomethylating Agents in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 61.	1.3	5
28	Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status. <i>Blood Advances</i> , 2020, 4, 845-854.	2.5	11
29	TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. <i>Cell</i> , 2020, 182, 297-316.e27.	13.5	63
30	Clonal hematopoiesis and inflammation: Partners in leukemogenesis and comorbidity. <i>Experimental Hematology</i> , 2020, 83, 85-94.	0.2	77
31	Genetics and epigenetics of leukemia and lymphoma: from knowledge to applications, meeting report of the Josep Carreras Leukaemia Research Institute. <i>Hematological Oncology</i> , 2020, 38, 432-438.	0.8	6
32	Genomic characterization of diffuse large B-cell lymphoma transformation of nodular lymphocyte-predominant Hodgkin lymphoma. <i>Leukemia</i> , 2020, 34, 2238-2242.	3.3	6
33	High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 1666-1677.	3.3	91
34	Restoration of TET2 deficiency inhibits tumor growth in head neck squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 329-329.	0.7	12
35	A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. <i>Cancer Cell</i> , 2020, 37, 551-568.e14.	7.7	589
36	Epigenetic Mechanisms in Leukemias and Lymphomas. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a034959.	2.9	14

#	ARTICLE	IF	CITATIONS
37	Estrogen Reverses HDAC Inhibitor-Mediated Repression of Aicda and Class-Switching in Antibody and Autoantibody Responses by Downregulation of miR-26a. <i>Frontiers in Immunology</i> , 2020, 11, 491.	2.2	13
38	Mouse Models in the Study of Mature B-Cell Malignancies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a034827.	2.9	3
39	The Role of Epigenetic Mechanisms in B Cell Lymphoma Pathogenesis. <i>Annual Review of Cancer Biology</i> , 2021, 5, 311-330.	2.3	3
40	Diagnosis and treatment of lymphomas in the era of epigenetics. <i>Blood Reviews</i> , 2021, 48, 100782.	2.8	7
41	Follicular lymphoma dynamics. <i>Advances in Immunology</i> , 2021, 150, 43-103.	1.1	19
42	TET-Mediated Epigenetic Regulation in Immune Cell Development and Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 623948.	1.8	27
43	Non-epigenetic heterogeneity, altered cell fate and differentiation therapy. <i>EMBO Molecular Medicine</i> , 2021, 13, e12670.	3.3	22
44	Insights into clonal hematopoiesis and its relation to cancer risk. <i>Current Opinion in Genetics and Development</i> , 2021, 66, 63-69.	1.5	20
45	TETology: Epigenetic Mastermind in Action. <i>Applied Biochemistry and Biotechnology</i> , 2021, 193, 1701-1726.	1.4	22
46	Real-life targeted next-generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network. <i>British Journal of Haematology</i> , 2021, 193, 1110-1122.	1.2	8
47	Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma. <i>Blood Cancer Discovery</i> , 2021, 2, 216-225.	2.6	22
48	Epigenetic gene regulation in plasma cells. <i>Immunological Reviews</i> , 2021, 303, 8-22.	2.8	10
49	Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL). <i>Current Cancer Drug Targets</i> , 2021, 21, 274-282.	0.8	10
50	An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach. <i>Cancers</i> , 2021, 13, 2893.	1.7	6
51	Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma. <i>Cancer Research and Treatment</i> , 2021, .	1.3	5
52	Decoding DNA methylation in epigenetics of multiple myeloma. <i>Blood Reviews</i> , 2022, 51, 100872.	2.8	12
53	Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models. <i>Frontiers in Immunology</i> , 2021, 12, 683597.	2.2	6
54	Forward and Reverse Genetics of B Cell Malignancies: From Insertional Mutagenesis to CRISPR-Cas. <i>Frontiers in Immunology</i> , 2021, 12, 670280.	2.2	1

#	ARTICLE	IF	CITATIONS
55	The unique biology of germinal center B cells. <i>Immunity</i> , 2021, 54, 1652-1664.	6.6	84
56	Mouse Models of Germinal Center Derived B-Cell Lymphomas. <i>Frontiers in Immunology</i> , 2021, 12, 710711.	2.2	6
57	Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes. <i>Frontiers in Immunology</i> , 2021, 12, 688493.	2.2	5
58	Loss of synergistic transcriptional feedback loops drives diverse B-cell cancers. <i>EBioMedicine</i> , 2021, 71, 103559.	2.7	1
59	Histone H1 Mutations in Lymphoma: A Link(er) between Chromatin Organization, Developmental Reprogramming, and Cancer. <i>Cancer Research</i> , 2021, 81, 6061-6070.	0.4	11
61	Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. <i>Nature Immunology</i> , 2021, 22, 240-253.	7.0	24
62	TET3 dioxygenase modulates gene conversion at the avian immunoglobulin variable region via demethylation of non-CpG sites in pseudogene templates. <i>Genes To Cells</i> , 2021, 26, 121-135.	0.5	3
63	Causes, effects, and clinical implications of perturbed patterns within the cancer epigenome. <i>Seminars in Cancer Biology</i> , 2022, 83, 15-35.	4.3	11
64	Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond. <i>Annals of Lymphoma</i> , 2020, 4, 7-7.	4.5	10
65	Roles of ten-eleven translocation family proteins and their O-linked &beta;-acetylglucosaminylated forms in cancer development (Review). <i>Oncology Letters</i> , 2020, 21, 1-1.	0.8	29
66	One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies. <i>Epigenomes</i> , 2021, 5, 22.	0.8	3
69	Active DNA demethylation—The epigenetic gatekeeper of development, immunity, and cancer. <i>Genetics &amp; Genomics Next</i> , 2021, 2, e10033.	0.8	3
70	Micro but mighty—Micronutrients in the epigenetic regulation of adaptive immune responses*. <i>Immunological Reviews</i> , 2021, , .	2.8	9
72	Molecular Subgroups of Diffuse Large B Cell Lymphoma: Biology and Implications for Clinical Practice. <i>Current Oncology Reports</i> , 2022, 24, 13-21.	1.8	15
73	Gene Regulatory Circuits in Innate and Adaptive Immune Cells. <i>Annual Review of Immunology</i> , 2022, 40, 387-411.	9.5	6
74	Dissecting TET2 Regulatory Networks in Blood Differentiation and Cancer. <i>Cancers</i> , 2022, 14, 830.	1.7	9
75	Marginal-Zone Lymphomas. <i>New England Journal of Medicine</i> , 2022, 386, 568-581.	13.9	53
76	Immune Epigenetic Crosstalk Between Malignant B Cells and the Tumor Microenvironment in B Cell Lymphoma. <i>Frontiers in Genetics</i> , 2022, 13, 826594.	1.1	6

#	ARTICLE	IF	CITATIONS
77	Ten-Eleven translocation $\beta$ 2 inactivation restrains IL $\beta$ -producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma. <i>Hepatology</i> , 2023, 77, 745-759.	3.6	9
78	The Role of Ten-Eleven Translocation Proteins in Inflammation. <i>Frontiers in Immunology</i> , 2022, 13, 861351.	2.2	9
79	Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma. <i>Frontiers in Immunology</i> , 2022, 13, 842439.	2.2	5
80	TET deficiency perturbs mature B cell homeostasis and promotes oncogenesis associated with accumulation of G-quadruplex and R-loop structures. <i>Nature Immunology</i> , 2022, 23, 99-108.	7.0	33
81	SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis. <i>Cancer Discovery</i> , 2022, 12, 1782-1803.	7.7	14
83	Metabolic control of epigenetic rearrangements in B cell pathophysiology. <i>Open Biology</i> , 2022, 12, 220038.	1.5	1
85	The epigenetic regulation of the germinal center response. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2022, 1865, 194828.	0.9	3
86	Mechanisms that regulate the activities of TET proteins. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	27
87	Genomic profiling for clinical decision making in lymphoid neoplasms. <i>Blood</i> , 2022, 140, 2193-2227.	0.6	63
89	Clonal germinal center B cells function as a niche for $\beta$ 2-cell lymphoma. <i>Blood</i> , 2022, 140, 1937-1950.	0.6	17
90	Evidence-based review of genomic aberrations in diffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS): Report from the cancer genomics consortium lymphoma working group. <i>Cancer Genetics</i> , 2022, 268-269, 1-21.	0.2	0
91	Epigenetic remodeling by vitamin C potentiates plasma cell differentiation. <i>ELife</i> , 0, 11, .	2.8	7
92	Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	6
93	Distinct B-Cell Specific Transcriptional Contexts of the BCL2 Oncogene Impact Pre-Malignant Development in Mouse Models. <i>Cancers</i> , 2022, 14, 5337.	1.7	2
94	A Tet-a-Tet in T follicular helper cell lymphoma. <i>Blood</i> , 2022, 140, 1919-1921.	0.6	1
95	Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1727.	1.8	6
96	The emerging role of TET enzymes in the immune microenvironment at the maternal-fetal interface during decidualization and early pregnancy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
97	Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment. <i>Blood Cancer Journal</i> , 2023, 13, .	2.8	8

#	ARTICLE	IF	CITATIONS
98	Roles of G4-DNA and G4-RNA in Class Switch Recombination and Additional Regulations in B-Lymphocytes. <i>Molecules</i> , 2023, 28, 1159.	1.7	5
99	Clonal Hematopoiesis: Origins and determinants of evolution. <i>Leukemia Research</i> , 2023, 129, 107076.	0.4	2
100	COVID-19 and the Genetics of Inflammation. <i>Critical Care Medicine</i> , 2023, 51, 817-825.	0.4	3
101	Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations. <i>American Journal of Hematology</i> , 2023, 98, 951-964.	2.0	2
102	Clinical and Mechanistic Implications of R-Loops in Human Leukemias. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5966.	1.8	2
103	Clonal haematopoiesis and dysregulation of the immune system. <i>Nature Reviews Immunology</i> , 2023, 23, 595-610.	10.6	18
104	What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias?. <i>Leukemia</i> , 2023, 37, 1186-1190.	3.3	2
105	SOHO State of the Art Updates and Next Questions   New Pathways and New Targets in PTCL: Staying on Target. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 561-574.	0.2	2
110	TET (Ten-eleven translocation) family proteins: structure, biological functions and applications. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	11
111	Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	0
116	Inferring the Cancer Cellular Epigenome Heterogeneity via DNA Methylation Patterns. <i>Cancer Treatment and Research</i> , 2023, , 375-393.	0.2	0
118	Molecular Pathogenesis of B-Cell Lymphomas. , 2024, , 309-333.		0